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Abstract
Myc has been intensely studied since its discovery more than 25
years ago. Insight has been gained into Myc’s function in normal
physiology, where its role appears to be organ specific, and in
cancer where many mechanisms contribute to aberrant Myc
expression. Numerous signals and pathways converge on Myc,
which in turn acts on a continuously growing number of identified
targets, via transcriptional and nontranscriptional mechanisms. This
review will concentrate on Myc as a signaling mediator in the
mammary gland, discussing its regulation and function during
normal development, as well as its activation and roles in breast
cancer.
Introduction
Since the early 1980s, numerous investigations have focused
on c-Myc to explore its role in normal organ physiology, as well
as in tumor biology [1,2]. The focus of the present review, c-
Myc (hereafter referred to as Myc), is the cellular homolog of
the avian retroviral oncogene v-myc and, together with N-myc
and L-myc, comprises the family of myc proto-oncogenes. The
half-lives of Myc mRNA and protein are short, allowing for tight
and rapid regulation of Myc levels, which occurs via numerous
transcription factors (TFs) and signaling pathways. Proteins
that directly bind the promoter or indirectly influence promoter
activity have been reviewed recently [3]. To provide some
insight into the complexity of Myc regulation, we will mention a
few of the factors and pathways that impact on its expression,
many of which were shown to be essential during mammary
gland development [4].
The myc promoter contains TF binding sites for Myc (auto-
suppression), estrogen receptor (ER) alpha, T-cell factor
(TCF) 4, Notch/C promoter-binding factor 1 (Cbf1), E2F,
Fos/Jun, signal transducer and activator of transcription (Stat) 3,
NF-κB, Smads and others. TFs that occupy or regulate the
myc promoter without specific binding sites include p53,
CCAAT/enhancer binding protein beta, and Stat5. Moreover,
numerous signaling pathways that are frequently deregulated
in human cancer influence myc expression; for example, rat
sarcoma (Ras)/extracellular signal-related kinase (Erk) and
phosphoinositide 3-kinase (PI3K)/serine/threonine kinase Akt
(Akt). Post-translational modifications of Myc include phos-
phorylation, ubiquitinylation and acetylation, and their effects
on Myc activity have been reviewed [5].
The Myc protein is a basic helix–loop–helix TF that must
heterodimerize with the abundantly expressed Max to regu-
late transcription. Myc–Max dimers bind to hexameric DNA
sequences (E-box) and activate transcription by recruiting
multiple coactivators [1]. In contrast, when dimerized with
basic helix–loop–helix proteins such as Mad or Mnt, Max
binds to E-boxes but represses transcription. Myc can also
act as a transcriptional repressor via different mechanisms,
often involving interaction with Miz1 (for reviews of Myc
transcriptional activity, see [1,6]). It is now well accepted that
Myc acts as a relatively weak activator of RNA polymerase II-
driven transcription for a large set of target genes, thereby
affecting cell cycle, cell growth and metabolism, cell death,
adhesion, angiogenesis and other functions (to date, almost
1,700 targets on Myc Cancer Gene [7,8]). Furthermore, Myc
affects RNA polymerase I- and III-mediated transcription [1],
thus regulating ribosome biogenesis and translation.
Nontranscriptional roles for Myc in DNA replication and in
translation have also been reported recently [9].
Considering the large number of receptors, hormones,
paracrine factors and other signaling molecules that can
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impact on Myc levels, it is likely that Myc has a variety of
functions throughout normal mammary gland development,
downstream of one or more of these inputs. To date,
however, there are only a few studies on the physiological
role of Myc in the mammary gland. In this review we present
what is known about Myc from transgenics and conditional
knockout models, and also include indirect evidence
implicating Myc based on results from other studies. We shall
discuss the potential inputs activating Myc during develop-
ment and the ensuing outputs of Myc activity. A summary of
the discussion on the role of Myc in normal development is
shown in Figure 1.
Embryogenesis
Development of the mammary gland begins at embryonic day
10 as an appendix of the ventral skin, with formation of the
milk line followed by appearance of placodes [10]. The
ErbB4 ligand, Neuregulin3 (Nrg3), was identified as a
specification signal for placode formation. Based on this,
Keratin14 (K14)-Nrg3 transgenic mice expressing Nrg3
throughout the basal layer of the epidermis, including the
stem and progenitor cells, were investigated [11]. Ectopic
Nrg3 expression resulted in hyperplastic epidermis and
formation of supernumerary placodes. Interestingly, the skin
of K14-Nrg3 mice displayed increased Myc expression and
decreased levels of α6-integrin and β1-integrin, which are
adhesion receptors highly expressed in adult mammary stem
cells (SCs) [12]. While the direct stimulus of Myc expression
is unknown, it seems to be an important mediator of the
phenotype observed in K14-Nrg3 mice, as strong similarities
were found in a K14-Myc model where Myc is activated in the
epidermis [11]. Nrg3 therefore possibly has a role in promo-
ting mammary lineage commitment and in the regulation of
SC fate via Myc.
Mammary stem cells
While these results suggest a role for Myc in embryonic
development, its role in adult mammary SCs has not yet
been analyzed. A function for Myc in mammary SCs seems
likely, however, based on its role in other well-characterized
models [1,13]. In the hematopoietic system, the balance
between SC self-renewal and differentiation is controlled by
Myc levels, which in turn regulate expression of adhesion
molecules such as N-cadherin and β1-integrin [14]. In
addition, the Wnt and Notch signaling pathways have been
proposed to play important roles in mammary SCs [13], and
their effector proteins – β-catenin/TCF and Notch
intracellular domain (NIC)/Cbf1, respectively – each have
binding sites on the Myc promoter [3]. Furthermore, a
transgenic model expressing stabilized β-catenin in basal
cells, which are believed to contain the SC population [12],
displayed upregulation of Myc [15]. Finally, the HC11
mammary epithelial cell line, which has SC-like properties,
might be an interesting model to explore Myc function, since
Myc levels are downregulated when these cells are induced
to differentiate [16].
Puberty and pregnancy
The steroid hormones estrogen and progesterone, as well as
the prolactin receptor binding peptides prolactin and
placental lactogen, dominate the extensive developmental
changes occurring during puberty and pregnancy [4,17].
Both estrogen and progesterone are able to directly stimulate
Myc expression via an estrogen response element [18] and a
progesterone receptor regulatory element [19]. While Myc is
expressed at low levels in prepubertal and virgin glands, it
reaches its highest expression levels between days 6.5 and
12.5 of pregnancy, after which the RNA level slowly returns
to baseline until parturition [20].
Interestingly, Myc was shown to be directly downstream of
estrogen and progesterone in breast cancer cells,
stimulating their proliferation [21,22], but one of the major
differences between normal breast and malignant breast is
that the estrogen- and progesterone receptor-positive cells
do not proliferate during normal development. Instead, by
producing paracrine mediators, estrogen and progesterone
stimulate proliferation of neighboring cells via amphiregulin
[23] and Wnt4 [24], respectively. Other growth factors,
such as epidermal growth factor or receptor activator of NF-
κB ligand, have also been shown to act as paracrine
mediators during mammary gland development [25]; and
importantly, Wnt, epidermal growth factor and receptor
activator of NF-κB ligand might all affect Myc levels directly
or indirectly [3].
Although no study has yet addressed the contribution of Myc
to pubertal development and early pregnancy, it is very likely
that Myc is induced via paracrine signals, and, at least early in
pregnancy when Myc levels are highest, Myc might promote
proliferation. Importantly, different Myc targets such as cyclin-
dependent kinase (Cdk) 4, nucleophosmin and nucleolin are
also highly expressed at this time [20] – prompting us to
speculate that Myc might not only have a direct role in
proliferation, but also in the synthesis of ribosomal
components required for rapid growth during pregnancy.
A transgenic model revealed why it is important for Myc levels
to decrease, starting at 12.5 days of pregnancy, and to
remain low until parturition. Using a doxycycline inducible
model (MMTV-rtTA/TetO-MYC (MTB/TOM)) [26], it was
shown that transient overexpression of Myc between days
12.5 and 15.5 of pregnancy induced a lactation failure [27].
Abnormal Myc expression was shown not only to induce
proliferation, but also to promote precocious Stat5 activation
and differentiation, followed by premature involution,
triggered by milk stasis. Decreased levels of Caveolin1
(Cav1), a direct target of Myc repression [7], were shown to
be responsible for the phenotype. Cav1 is a negative regu-
lator of Janus kinase2–Stat5 signaling, and Cav1–/– mammary
epithelial cells show hyperactivation of Stat5 and spon-
taneous milk production [28], similar to what is observed
when Myc is elevated late in pregnancy.These results demonstrate an important characteristic of Myc –
namely, the effects of Myc are dependent upon the
developmental stage of the mammary gland. Myc
overexpression between 12.5 and 15.5 days of pregnancy
was necessary and sufficient to induce the observed
phenotype, while overexpression during other short intervals
(for example, 9.5 to 12.5 days) did not result in lactation
failure [27]. Deregulated Myc therefore leads to a premature
decrease in Cav1, thereby removing its restraining influence
on prolactin receptor–Janus kinase2–Stat5 signaling.
Lactation
In many cell types Myc is downregulated when cells undergo
terminal differentiation. Indeed, Myc RNA levels do drop
during lactation to below those levels found in the virgin gland
[20]; however, the molecular reason for this dramatic
decrease is not known. The mammary gland as a milk factory
produces immense amounts of lipids, lactose and proteins,
and most of its energy is devoted to milk component
synthesis. Considering the importance of Myc in energy and
glucose metabolism as well as ribosome biogenesis and
translation [1], it is possible that, even despite its low levels,
Myc has an essential function during lactation.
Indeed, data from our laboratory revealed a novel role for Myc
in the mammary gland using a conditional knockout
approach. In c-mycfl/flWAP(whey acidic protein)iCre mice,
loss of Myc occurs exclusively in luminal alveolar cells starting
from mid-pregnancy. We show that milk production was
reduced in Myc mutant mothers, while milk composition was
unchanged between wild-type and mutant mothers [29].
Electron microscopy revealed that there were less secretory
vesicles budding from the endoplasmic reticulum in lactating
mutant cells, suggesting a decreased protein synthesis. In
polysomal fractionation experiments we found that translation
efficiency was generally decreased in lactating, Myc-deficient
mammary glands. Furthermore, we observed reduced
expression levels of ribosomal proteins and RNA, as well as
proteins  involved in translation and ribosome biogenesis.
Although compensation by N-Myc or L-Myc cannot be
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Figure 1
Ins and outs of the ‘black box’ MYC during normal mammary gland development. The diagram displays the models (italic, top) used to investigate
the various inputs and outputs of Myc (green boxes). Speculations based on other model systems that have not yet been shown in the mammary
gland are presented in red. Inputs are signaling molecules that are known or suggested to impact on Myc levels; inputs are not applicable (n.a.) in
transgenic models with genetically deregulated Myc levels. The outputs are, where available, direct targets of Myc transcriptional activity and
general biological functions described for Myc at the specific developmental stage (italic, bottom). During embryogenesis, transgenic expression of
Neuregulin3 (Nrg3), a major factor controlling mammary placode development, induced high Myc levels, thereby changing the proliferative and
adhesive properties of cells [11]. The speculated role of Myc in mammary stem cells (SCs) is mostly based on data from hematopoietic SCs and
the known importance of Wnt and Notch pathways in other SC types [13]. Myc’s role during puberty and early pregnancy has not yet been
analyzed, but as various steroids and paracrine factors can induce its expression [3] Myc might play a role in promoting proliferation and cell
growth via its numerous cell cycle and translation-related targets. A transgenic mouse model (MMTV-rtTA/TetO-MYC (MTB/TOM)) revealed that
Myc overexpression during late pregnancy leads to precocious proliferation and differentiation via repression of Caveolin1 (Cav1) and signal
transducer and activator of transcription (Stat) 5 hyperactivation [27]. Despite its low levels during lactation, Myc has an important role in mRNA
translation, as shown in our own laboratory using mammary glands conditionally lacking Myc (Myc-CKO) [29]. Finally, in Socs3 conditional
knockout (CKO) mice it was shown that increased Stat3 activation leads to accelerated apoptosis via high levels of Myc, suggesting a direct role
for Myc downstream of Stat3 in involution [31]. More detailed discussion can be found in the text. K14, Keratin14; KO, knockout; N-Cad, N-
cadherin.excluded, neither was found upregulated in c-Myc mutant
glands. These results highlight Myc’s importance for mammary
gland function even when endogenous levels are low.
Involution
The impact of Myc on apoptosis has been widely studied in
many systems [2]. In the mammary gland, the high levels of
apoptosis during the first phase of involution are promoted by
the leukemia inhibitory factor–Stat3 axis [30]. Compared with
its low expression in lactating glands, higher Myc levels are
detected during involution [20]. Importantly, a role for Myc
during the first apoptotic phase was uncovered in mice with a
conditional deletion of Socs3 (Socs3–/flWAPiCre), a negative
regulator of leukemia inhibitory factor–Stat3 signaling [31].
Socs3-deficient glands displayed accelerated apoptosis
accompanied by elevated levels of p-Stat3 and Myc, which is
a direct Stat3 target gene.
To further analyze Myc’s function in apoptosis, the
doxycycline-inducible MTB/TOM model described above [26]
was used, giving more evidence for a direct role of Myc in
involution. Overexpression of Myc prior to forced weaning
caused a dramatic acceleration of involution, accompanied by
increased apoptosis and high levels of the pro-apoptotic
proteins Bax, E2F-1 and p53, which have all been described
as direct or indirect Myc targets.
The conclusions based on those two models suggest that
Myc acts as a central mediator of apoptotic signaling in the
mammary gland, being a direct target of Stat3 and inducing
expression of pro-apoptotic genes.
Background on Myc in breast cancer
Alterations in Myc have been found in many types of tumors.
At the genomic level these include gene amplification,
chromosomal translocations and point mutations. Further-
more, Myc is regulated by multiple signals that control
promoter activity, transcriptional elongation and translation,
as well as by post-translational modifications that control
Myc’s transcriptional targets as well as protein stability. Since
most tumors have numerous alterations in signaling
cascades, Myc is likely to be deregulated by some
mechanisms in most cancers.
Considering breast cancer, amplification is the most
commonly described alteration. The MYC amplicon on
chromosome 8q23-24 was one of the first consistent genetic
alterations found [32]. Results from a meta-analysis of breast
tumors yielded a frequency of 15.7% for the MYC amplicon,
with a range of 4 to 52% depending on the study [21,33].
MYC  amplification is found in a high proportion of tumors
with Brca1 alterations, as well as in ERα-negative, basal-like
tumors [34,35]. Despite intense screening efforts, point
mutations of Myc have not been described in breast or other
carcinomas [36]. Other mechanisms promoting increased
Myc levels, however, have been found. The ubiquitin ligase
F-box and WB repeat domain containing 7, which catalyzes
polyubiquitination of Myc and ensuing degradation, is often
mutated or downregulated in breast cancer [37]. Moreover,
the de-ubiquitinating enzyme ubiquitin-specific protease 28 –
which antagonizes F-box and WB repeat domain containing 7,
thereby stabilizing Myc – has been found overexpressed in a
small panel of breast tumors [38]. In addition to these breast
tumor-specific alterations, it is possible that Myc is de-
regulated in most breast tumors since the normal tight control
that is exerted on Myc at multiple levels is impaired in
essentially all cancer cells.
What is the output of deregulated Myc in breast cancer? Myc
levels respond to proliferative and anti-proliferative stimuli,
and many reported Myc target genes, such as cyclin D2,
Cdk4 and the Cdk inhibitor p21Cip1, are important regulators
of proliferation [2]. A major mechanism underlying Myc’s role
in breast cancer is activation of cyclin E–Cdk2 via repression
of p21Cip1 [21]. Myc deregulation not only impacts on
proliferation, but on various other processes like survival and
apoptosis.
Here we would like to mention Myc and translational control,
since we have recently shown an important role for Myc in
translation also during mammary gland development [29].
Generation of the Eμ-Myc B-cell leukemia model in mice with
heterozygosity in the gene encoding the L24 ribosomal protein
restored normal levels of protein synthesis in the leukemic
cells, thereby suppressing Myc’s oncogenic potential [39].
These results show that, in addition to proliferative effects,
abnormal Myc activation also deregulates protein synthesis,
which in this model is necessary for oncogenesis.
Considering the broad-ranging effects of Myc, the outcome
of its activation in breast cancer is likely to be dependent
upon the cellular context. Indeed, using a siRNA approach to
knockdown Myc in a panel of breast cancer cell lines, and
combining this with a genomic and phenotypic analysis,
revealed that selectively regulated target genes in each cell
line were responsible for the differential effects resulting from
Myc loss. A comprehensive list of potential Myc targets in the
BT-474, MCF-7 and MDA-MB-231 breast cancer cell lines
can be found in Cappellen and colleagues’ study [40]. A
summary of the discussion on the role of Myc in cancer is
shown in Figure 2.
Myc and mammary cancer
Myc was the first oncogene tested for mammary tumor-
forming potential using the mouse mammary tumor virus
(MMTV)-long terminal repeat to drive its expression. Tumor
incidence in MMTV-Myc transgenic females was high;
however, the kinetics of tumor appearance suggested that
Myc expression alone was not sufficient to induce cancer
[41]. Indeed, double transgenics expressing Myc and mutant
Hras showed more rapid mammary tumor development [2].
More recently, it was shown that Myc induction using the
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mammary tumors, with approximately one-half also harboring
activating Kras2 mutations. Interestingly, these tumors did not
regress following Myc deinduction, demonstrating that Hras
mutations not only change tumor kinetics but also cause
progression to Myc independency [26].
Myc and Notch
Each membrane spanning Notch receptor is proteolytically
processed in response to ligand binding, releasing NIC, which
converts the nuclear Cbf1 repressor to a transcriptional
activator. A link between aberrant Notch signaling and
mammary cancer was first discovered in MMTV-induced
tumors with proviral DNA integrated within the Notch4 gene,
leading to constitutive NIC expression. Different mechanisms
activate Notch signaling in human breast cancer [42,43]. For
example, coexpression of Jagged1 ligand and Notch
receptors has been found in breast cancers, in particular the
triple-negative (negative for ERα, for progesterone receptor
and for ErbB2) subtype [44], suggesting an autocrine
mechanism of Notch pathway activation. Furthermore, levels
of Numb, a negative regulator of Notch, were shown to be
low in ~50% of primary breast tumors [45], which could
contribute to maintenance of pathway activity.
Based on the observation that mammary tumors in the
MMTV-NIC transgenics presented elevated Myc, its role in
Notch transformation was examined in mice with floxed Myc
alleles [43]. Conditional ablation of Myc using the WAPCre
transgene revealed that Myc was indispensable for develop-
ment of NIC-driven mammary tumors. This contribution of Myc
to Notch-induced tumorigenesis is interesting especially
when comparing it with Wnt pathway-driven models (see
below). Moreover, Myc was shown to be a direct target of the
Notch pathway, since a complex of NIC and Cbf1 was
detected on the Myc promoter. The Cbf1 binding site on the
human Myc promoter is conserved, and immunohisto-
chemistry revealed that there was a significant correlation
between high Myc levels and NIC in human breast tumors
[43]. It is intriguing that coexpression of Jagged ligand and
Notch receptors is found in triple-negative breast tumors
[44], a subgroup that also has high Myc activity [46].
Myc and the Wnt pathway
Wnt1 was the first identified oncogene activated by MMTV
insertional mutagenesis. Wnt-mediated activation of the
canonical pathway leads to β-catenin stabilization, TCF
binding and transcriptional activation of Myc. Mammary
tumors arising in Wnt1 transgenics [47] and models driven
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Figure 2
Aberrant Myc expression causes mammary cancer. Myc is deregulated in most mammary tumors by multiple mechanisms, including gene
amplification, or aberrant expression due to alterations in signaling pathways that influence Myc RNA or protein levels as well as its transcriptional
activity. Each of the indicated proteins or pathways impacts on Myc expression or activity in mammary cancer. Specifically, the Notch and Wnt
pathway effectors, Notch intracellular domain/C promoter-binding factor 1 and β-catenin/T-cell factor, respectively, as well as estrogen receptor
alpha (ERα), bind the Myc promoter, thereby stimulating transcription. Dysregulation of transforming growth factor beta (TGFβ) and Brca1 in
mammary cancer has been reviewed recently [34]. TGFβ, via Smads, suppresses Myc expression, while Brca1, which is frequently deregulated in
ERα-negative, basal-like breast cancer, normally blocks Myc transcriptional activity. The ubiquitin-specific protease ubiquitin-specific protease 28
(USP28) was found overexpressed in breast tumors [38] and stabilizes Myc via antagonizing F-box and WB repeat domain containing 7 (FBW7),
which is frequently lost or mutated in breast tumors [37]. Finally, ErbB2 activation, which is also regulated by ERα, stimulates pathways like rat
sarcoma/extracellular signal-related kinase (Ras/Erk) and phosphoinositide 3-kinase/serine/threonine kinase Akt (PI3K/Akt) that influence Myc RNA
and protein levels. See text for further details. Myc is an activator of RNA polymerase II-driven transcription for multiple target genes [2] and also
affects RNA polymerase I- and III-mediated transcription, thus regulating ribosome biogenesis and translation. In cancer cells, the outcome of
deregulated Myc will be wide-ranging considering that Myc influences the cell cycle, protein synthesis, cell growth and metabolism, cell death,
genomic instability, tumor-induced angiogenesis, adhesion, as well as other cellular functions. This is exemplified by examining the effects of Myc
knockdown in breast cancer cell lines, where a genomic and phenotypic analysis revealed that selectively regulated target genes in each cell line
were responsible for the differential effects resulting from Myc loss [40].by a β-catenin-stabilized mutant [15] show elevated levels of
Myc. Human breast tumors, unlike colon cancer, do not
possess Wnt pathway-activating mutations. Deregulation of
Wnt signaling appears to occur by autocrine mechanisms,
however, since multiple Wnt ligands and Frizzled receptors
are coexpressed [48], and the negative Wnt pathway
regulator – secreted Frizzled-related protein (sFRP1) – is
often absent [49]. A positive feedback loop has also been
described for Myc and the Wnt pathway. In telomerase-
immortalized, Myc-transformed human mammary epithelial
cells, Myc was shown to repress sFRP1 and Dickkopf 1,
another negative pathway regulator, thereby contributing to
activation of canonical Wnt signaling [50]. Along the same
lines, Myc knockdown in MDA-MB-231 tumor cells increased
Dickkopf 3 expression [40].
What is Myc’s role in tumors induced by Wnt pathway
activation? The dependency of Wnt-driven mouse mammary
tumors on Myc expression has not been tested. In other
tumor models driven by adenomatosis polyposis coli (APC)
loss, the importance of Myc has been examined using organ-
specific Cre recombinase-mediated deletion of floxed Myc
alleles. In the intestines, Myc deletion reversed the tumor
phenotype induced by APC loss, and it was shown that the
majority of Wnt targets in the intestines were Myc dependent
[51]. In striking contrast, Myc deletion had no affect on the
phenotype of APC loss in the liver, where most Wnt target
genes were β-catenin dependent but Myc independent [52].
These two studies [51,52] reveal that the importance of Myc
in a particular tumor model is very specific and can differ as
already discussed for the normal organ-specific Myc
functions. As discussed above, deregulated Myc might
enforce autocrine Wnt pathway activity in human tumors by
repressing negative regulators such as sFRP1. Other
potential roles for Myc have not been examined; however,
blockade of the Wnt pathway usually results in lowering Myc
levels. Stable expression of sFRP1 in MDA-MB-157 and
MDA-MB-231 breast tumor cell lines blocks proliferation of
both cell lines, and Myc RNA was decreased in the former
[53] while Myc protein was lower in the latter [49]. In a panel
of breast cancer cell lines, siRNA-mediated knockdown of
Dishevelled, an essential mediator of Wnt signaling, led to
lower Myc and decreased proliferation in most cell lines [54].
In summary, the current data suggest that, in mouse and
human mammary tumors with constitutive Wnt signaling, Myc
levels are elevated and might have a role in transformation.
Myc and ErbB2
Amplification of ERBB2 leading to receptor overexpression is
found in 20 to 25% of primary breast tumors. In these tumors,
constitutive ErbB2 activation stimulates numerous intra-
cellular signaling pathways including Ras/Erk and PI3K/Akt,
both of which impact on Myc transcription and protein
stability. The role of Myc has been examined in the ErbB2-
overexpressing SKBr3 and BT-474 breast tumor cell lines.
Treatment of both with the ErbB2-specific antibody trastuzu-
mab caused a cell cycle block that was accompanied by a
decrease in PI3K/Akt pathway activity, and by downregulation
of Myc and D-type cyclins [55]. Interestingly, ectopic
expression of Myc in SKBr3 cells partially rescued the cells
from functional ErbB2 inactivation [56], pointing to the
importance of Myc as an ErbB2 effector.
Myc and estrogen receptor alpha
In the normal breast, both rodent and human, a major role of
the ERα-positive cells is to act as sensors to relay a
proliferative signal to neighboring cells. In contrast, many
breast tumor cells are ERα-positive, and they have not only
acquired the potential to proliferate in response to steroid
hormones but are also dependent upon them for survival
[21,57]. Since Myc is an ERα target, it is important to
understand whether Myc has a role in acquisition of this
phenotype. Moreover, since patients whose tumors are ERα-
positive are treated with anti-estrogen therapy, Myc’s role in
response or resistance is also of high interest. Unfortunately,
consistent clinical data relating MYC amplification or expres-
sion levels to endocrine therapy response are not available
[21]. Overexpression of ErbB2 has been correlated with de
novo and acquired endocrine resistance [57], however, and
Myc is an ErbB2 effector.
The role of Myc in ERα signaling has been well characterized
in the MCF-7 breast tumor cell line [21]. Myc RNA increases
rapidly in response to estrogen treatment of these cells, and
Myc knockdown impairs the ability of estrogens to stimulate
proliferation. Furthermore, Myc overexpression in cells
arrested by ERα antagonists overcomes the proliferative
block. Interestingly, adaptation of MCF-7 cells to growth in
estrogen-deprived medium is associated with upregulation of
ERα-regulated target genes, including Myc [58], suggesting
a mechanism whereby Myc maintains an important role in
proliferation and survival even in the absence of ERα activity.
It should also be mentioned that ERα cross-regulates ErbB2,
which in turn impacts on Myc via activation of downstream
signaling pathways [57].
From transcriptome and network analyses, the close link
between Myc and ERα signaling has become even more
apparent. MCF-7 cells show a high level of overlap between
ERα-regulated and Myc-regulated genes. Indeed, more than
50% of the estrogen-responsive genes are also Myc targets
[59]. Moreover, a meta-analysis of transcriptional and
pathway data, carried out on primary breast tumors, revealed
that Myc activity is elevated in ERα-negative, basal-like breast
cancers, as measured by target gene levels [46].
In summary, these data led to the proposal that elevated Myc
activity present in ERα-negative breast tumor cells mimics the
activity of estrogen on ERα-positive breast tumor cells
[46,59].
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Considering that Myc deregulation is so common in breast
cancer, Myc has been examined as a prognostic factor and
as a predictive factor. Indeed, MYC amplification is asso-
ciated with aggressive clinical features including high grade
and lymph node positivity, and correlates with poor patient
outcome [34]. A major interest in breast cancer is the use of
genetic alterations to categorize patients into treatment
groups; a good example being detection of the ERBB2
amplicon for trastuzumab treatment. Gene expression signa-
tures are also being generated in order to provide predictive
data on patient response to standard chemotherapeutics and
to targeted therapy. In one study of chemotherapy-treated
breast cancer patients, an attempt to correlate Myc pathway
activity with response yielded inconsistent results. The group
with Myc and Ras pathway activation had a high percentage
of responders, while patients whose tumors had Myc and
E2F pathway activity responded poorly [60]. These results
underscore the difficulty of using Myc levels alone as a
predictive or prognostic factor, and emphasize the fact that
the cellular context of Myc expression and activity determine
the outcome.
Approaches to target Myc activity in tumors are also under
consideration [34,61]. Although targeting Myc is appealing,
there are many difficulties associated with altering trans-
cription factor activity. Considering the variety of kinase
inhibitors currently available, it is worth considering their use
in breast tumors with Myc deregulation. Based on the
molecular concepts analysis [62] of the Myc pathway
activation signature in cancer, and on the identification of the
genes downregulated in MCF-7 cells treated with
wortmannin and LY-294002, there is reason to believe that
PI3K inhibitors might be especially potent in breast cancers
with high Myc activity. As discussed [46], ERα-negative,
basal-like breast tumors with high Myc activity might be
particularly susceptible to PI3K inhibitors.
Conclusion
Clearly, there are numerous signaling events in the
development of the mammary gland that can be mediated, at
least in part, via Myc. Using transgenic models, functions for
Myc – some potential, others data based – have been
discussed for embryonic development, pregnancy, lactation
and involution. Furthermore, results from other model systems
suggest that Myc could play a role in stem cell fate, as well as
during early pregnancy, where Myc expression levels are
highest in the normal gland. Even more efforts have been
made to investigate Myc’s role in transformation, as
deregulation of Myc via amplification, overexpression or
stabilization of the protein is a frequent event in breast
cancer. Signaling pathways implicated in breast cancer, such
as ERα, ErbB2, Notch and Wnt, all contribute to aberrant
Myc levels or activity. The challenge for future studies will be
to reveal the suitability of targeting Myc for breast cancer
treatment, either by direct inhibition or by indirectly targeting
another pathway.
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